• Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648. Comprehensive review on AIHA, first international consensus on diagnosis and treatment.

Berentsen S, Barcellini W. Autoimmune Hemolytic Anemias. N Engl J Med. 2021;385:1407–19.

Article  CAS  PubMed  Google Scholar 

Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124:2930–6.

Article  CAS  PubMed  Google Scholar 

Dacie J. The auto-immune haemolytic anaemias: introduction. In: Dacie J, editor. The Haemolytic Anaemias, vol. 3. London: Churchill Livingstone; 1992. p. 1–5.

Google Scholar 

Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre. Br Med J (Clin Res Ed). 1981;282:2023–7.

Article  CAS  PubMed  Google Scholar 

Schubothe H. The cold hemagglutinin disease. Semin Hematol. 1966;3:27–47.

CAS  PubMed  Google Scholar 

Berentsen S, Tjønnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev. 2012;26:107–15.

Article  CAS  PubMed  Google Scholar 

Hill QA, Hill A, Berentsen S. Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. Blood Adv. 2019;3:1897–906.

Article  PubMed  PubMed Central  Google Scholar 

Shanbhag S, Spivak J. Paroxysmal cold hemoglobinuria. Hematol Oncol Clin North Am. 2015;29:473–8.

Article  PubMed  Google Scholar 

• Jacobs JW, Figueroa Villalba CA, Booth GS, Woo JS, Stephens LD, Adkins BD. Clinical and epidemiological features of paroxysmal cold hemoglobinuria: a systematic review. Blood Adv. 2023;7:2520-7. Recent review of all published cases of PCH, providing new data on an ultra-rare disease.

Berentsen S, Fattizzo B, Barcellini W. The choice of new treatments in autoimmune hemolytic anemia: How to pick from the basket? Front Immunol. 2023;14:1180509.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases. Blood. 1987;69:820–6.

Article  CAS  PubMed  Google Scholar 

Coombs RR, Mourant AE, Race RR. A new test for the detection of weak and incomplete Rh agglutinins. Br J Exp Pathol. 1945;26:255–66.

CAS  PubMed  PubMed Central  Google Scholar 

Meulenbroek EM, de Haas M, Brouwer C, Folman C, Zeerleder SS, Wouters D. Complement deposition in autoimmune hemolytic anemia is a footprint for difficult-to-detect IgM autoantibodies. Haematologica. 2015;100:1407–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berentsen S. Complement activation and inhibition in autoimmune hemolytic anemia: Focus on cold agglutinin disease. Semin Hematol. 2018;55:141–9.

Article  PubMed  Google Scholar 

Berentsen S. How I treat cold agglutinin disease. Blood. 2021;137:1295–303.

Article  CAS  PubMed  Google Scholar 

Rosse WF, Adams JP. The variability of hemolysis in the cold agglutinin syndrome. Blood. 1980;56:409–16.

Article  CAS  PubMed  Google Scholar 

Ulvestad E, Berentsen S, Bø K, Shammas FV. Clinical immunology of chronic cold agglutinin disease. Eur J Haematol. 1999;63:259–66.

Article  CAS  PubMed  Google Scholar 

Berentsen S, Röth A, Randen U, Jilma B, Tjønnfjord GE. Cold agglutinin disease: current challenges and further prospects. J Blood Med. 2019;10:93–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guenther A, Tierens A, Malecka A, Delabie J. The histopathology of cold agglutinin disease-associated B-Cell lymphoproliferative disease. Am J Clin Pathol. 2023;160:229–37.

Article  CAS  PubMed  Google Scholar 

•• Berentsen S, Barcellini W, D'Sa S, Randen U, Tvedt THA, Fattizzo B, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. 2020;136:480-8. The largest observational study of patients with confirmed CAD. Pivotal data on interpretation of biopsy findings. Long-term follow-up data from 2 prosepctive trials.

Hansen DL, Berentsen S, Fattizzo B, Hansen PL, Barcellini W, Frederiksen H. Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy. Am J Hematol. 2021;96:E262–5.

Article  CAS  PubMed  Google Scholar 

•• Randen U, Trøen G, Tierens A, Steen C, Warsame A, Beiske K, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014;99:497-504. First description of CAD-associated lymphoproliferative disorder.

Naresh KN, Rossi D, Chen X, Berentsen S, Randen U. Cold agglutinin disease. WHO Classification of Haematolymphoid Tumours, 5th Edition. Lyon: International Agency for Research on Cancer; 2022. p. 349. Online version available at https://tumourclassification.iarc.who.int/chaptercontent/63/.

Harboe M, van Furth R, Schubothe H, Lind K, Evans RS. Exclusive occurrence of K chains in isolated cold haemagglutinins. Scand J Haematol. 1965;2:259–66.

Article  CAS  PubMed  Google Scholar 

Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91:460–6.

PubMed  Google Scholar 

Jaffe CJ, Atkinson JP, Frank MM. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. J Clin Invest. 1976;58:942–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi J, Rose EL, Singh A, Hussain S, Stagliano NE, Parry GC, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood. 2014;123:4015–22.

Article  CAS  PubMed  Google Scholar 

Berentsen S. Sutimlimab for the treatment of cold agglutinin disease. Hemasphere. 2023;7:e879.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Röth A, Bommer M, Hüttmann A, Herich-Terhurne D, Kuklik N, Rekowski J, et al. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018;2:2543–9.

Article  PubMed  PubMed Central  Google Scholar 

•• Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, et al. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021;384:1323-34. Pivotal paper on complement inhibition with sutimlimab in cold agglutinin disease.

Berentsen S. New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia. Front Immunol. 2020;11:590. https://doi.org/10.3389/fimmu.2020.00590.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joly F, Schmitt LA, Watson PAM, Pain E, Testa D. The burden of cold agglutinin disease on patients’ daily life: Web-based cross-sectional survey of 50 American patients. JMIR Form Res. 2022;6:e34248.

Article  PubMed  PubMed Central  Google Scholar 

Broome CM, Cunningham JM, Mullins M, Jiang X, Bylsma LC, Fryzek JP, et al. Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis. Res Pract Thromb Haemost. 2020;. https://doi.org/10.1002/rth2.12333:928.

Kamesaki T, Nishimura JI, Wada H, Yu E, Tsao E, Morales J, et al. Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan. Int J Hematol. 2020;112:307–15.

Article  CAS  PubMed  Google Scholar 

Dacie J. Auto-immune haemolytic anaemia (AIHA): cold-antibody syndromes I: idiopathic types: clinical presentation and haematological and serological findings. In: Dacie J, editor. The Haemolytic Anaemias, vol. 3. London: Churchill Livingstone; 1992. p. 210–39.

Google Scholar 

Khwaja J, D’Sa S, Minnema MC, Kersten MJ, Wechalekar A, Vos JM. IgM monoclonal gammopathies of clinical significance: diagnosis and management. Haematologica. 2022;107:2037–50.

Article  CAS  PubMed  PubMed Central